AI Article Synopsis
- A new series of LpxC inhibitors, specifically pyridone methylsulfone hydroxamate 2a, is introduced.
- These new compounds have better solubility and free fraction compared to older biphenyl methylsulfone hydroxamates.
- They also show stronger antibacterial effectiveness against Gram-negative bacteria compared to other tested agents.
Article Abstract
The synthesis and biological activity of a new series of LpxC inhibitors represented by pyridone methylsulfone hydroxamate 2a is presented. Members of this series have improved solubility and free fraction when compared to compounds in the previously described biphenyl methylsulfone hydroxamate series, and they maintain superior Gram-negative antibacterial activity to comparator agents.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/jm2014875 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discovery of Novel Inhibitors of LpxC Displaying Potent in Vitro Activity against Gram-Negative Bacteria.
J Med Chem
January 2020
Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91 , CH-4123 Allschwil , Switzerland.
UDP-3--(()-3-hydroxymyristoyl)--glucosamine deacetylase (LpxC) is as an attractive target for the discovery and development of novel antibacterial drugs to address the critical medical need created by multidrug resistant Gram-negative bacteria. By using a scaffold hopping approach on a known family of methylsulfone hydroxamate LpxC inhibitors, several hit series eliciting potent antibacterial activities against Enterobacteriaceae and were identified. Subsequent hit-to-lead optimization, using cocrystal structures of inhibitors bound to LpxC as guides, resulted in the discovery of multiple chemical series based on (i) isoindolin-1-ones, (ii) 4,5-dihydro-6-thieno[2,3-]pyrrol-6-ones, and (iii) 1,2-dihydro-3-pyrrolo[1,2-]imidazole-3-ones.
View Article and Find Full Text PDFThe inhibitory and binding studies of methyl-sulfone hydroxamate based inhibitors against LpxC from drug resistant Moraxella catarrhalis using biophysical, biochemical and in silico approaches.
Int J Biol Macromol
October 2018
Department of Biotechnology, Indian Institute of Technology Roorkee, 247667, India. Electronic address:
Several reported potential compounds against UDP-3-O-(R-3-Hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) have shown large variation in the potency and efficacy. The differential susceptibility and selective binding of these inhibitors against LpxC are still unexplored. In the present work, we have characterized LpxC from Moraxella catarrhalis (McLpxC) and investigated its binding with potent inhibitors LpxC-2 and LpxC-4 using biochemical, biophysical and in silico approaches.
View Article and Find Full Text PDF3D-QSAR, Molecular Docking and Molecular Dynamics Simulation of Pseudomonas aeruginosa LpxC Inhibitors.
Int J Mol Sci
May 2017
College of Pharmacy and Biological Engineering, Key Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, Sichuan Industrial Institute of Antibiotics, Chengdu University, Chengdu 610106, China.
As an important target for the development of novel antibiotics, UDP-3--(-3-hydroxymyristoyl)--acetylglucosamine deacetylase (LpxC) has been widely studied. Pyridone methylsulfone hydroxamate (PMH) compounds can effectively inhibit the catalytic activity of LpxC. In this work, the three-dimensional quantitative structure-activity relationships of PMH inhibitors were explored and models with good predictive ability were established using comparative molecular field analysis and comparative molecular similarity index analysis methods.
View Article and Find Full Text PDFHeterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents.
Bioorg Med Chem Lett
November 2012
Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, CT 06340, USA.
The synthesis and antibacterial activity of heterocyclic methylsulfone hydroxamates is presented. Compounds in this series are potent inhibitors of the LpxC enzyme, a key enzyme involved in the production of lipopolysaccharide (LPS) found in the outer membrane of Gram-negative bacteria. SAR evaluation of compounds in this series revealed analogs with potent antibacterial activity against challenging Gram-negative species such as Pseudomonas aeruginosa and Klebsiella pneumoniae.
View Article and Find Full Text PDFPyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections.
J Med Chem
February 2012
Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States.
Article Synopsis
- A new series of LpxC inhibitors, specifically pyridone methylsulfone hydroxamate 2a, is introduced.
- These new compounds have better solubility and free fraction compared to older biphenyl methylsulfone hydroxamates.
- They also show stronger antibacterial effectiveness against Gram-negative bacteria compared to other tested agents.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!